Please ensure Javascript is enabled for purposes of website accessibility

Why Intercept Pharmaceuticals, Inc. Stock Broke Down in October

By George Budwell – Nov 12, 2018 at 9:24AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Interecept's stock fell victim to the industrywide downturn last month.

What happened

Intercept Pharmaceuticals (ICPT 1.48%), a mid-cap liver disease specialist, saw its shares sink by a whopping 24% last month, according to S&P Global Market Intelligence. What spooked investors so much?

Intercept's shares sank in response to the biotech industry's widespread downturn in October that was seemingly triggered by President Trump's escalating trade war with China. In brief, investors apparently decided to shun risky biotech stocks last month because of the uncertainty surrounding Trump's back-and-forth with China over tariffs.   

A doctor cupping his hand underneath a 3D image of a liver.

Image source: Getty Images.

So what

Prior to last month's sell-off, Intercept's shares were in the midst of long-tailed rally, sparked by the strong commercial performance of its primary biliary cholangitis drug, Ocaliva, this year. Even after this October swoon, for example, Intercept's shares are still up by over 86% for the year at the time of writing.

Now what

Can Intercept regain its footing? The answer to this all-important question seems to be a resounding "yes." Intercept, after all, is expected to roll out Ocaliva's initial late-stage data for its next major indication, nonalcoholic steatohepatitis (NASH), in the first half of next year.

The big deal is that NASH is a potentially fatal liver disease that reportedly afflicts upwards of 5% of all adults in the United States. Even so, there currently is no approved treatment for NASH -- potentially setting the stage for Ocaliva to become the first drug to market for this unmet medical need. Intercept is thus staring down a multibillion-dollar market opportunity with Ocaliva's NASH indication. That kind of monstrous commercial opportunity should eventually reignite Intercept's nearly yearlong rally. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.